HIGHFDA DRUG

Harbin Jixianglong Biotech Semaglutide Rx Compounding Recall (2026)

Harbin Jixianglong Biotech Co. recalled semaglutide for Rx compounding use distributed nationwide to healthcare providers in the United States. The recall cites CGMP deviations and failure to complete process validation and bacterial endotoxin method validation before distribution. Healthcare providers and patients should stop using this product immediately and contact the manufacturer or their CL

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
February 13, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
February 13, 2026
Hazard Level
HIGH
Brand
Harbin Jixianglong Biotech Co.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Harbin Jixianglong Biotech Co.
Product type
Semaglutide API (Rx compounding use)
Model numbers
CP-030-20250711, Exp. July 24, 2027
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    February 13, 2026

  2. Reported by FDA DRUG

    March 11, 2026

  3. RecallRadar source check

    March 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Harbin Jixianglong Biotech Co., Ltd. or your healthcare provider for guidance. Notification method: E-Mail

About This Product

Semaglutide is a GLP-1 receptor agonist used for diabetes and weight management in specialty settings. In Rx compounding, it is prepared for individualized dosing by healthcare providers.

Why This Is Dangerous

The CGMP deviations suggest the product may not have undergone validated sterility and endotoxin testing, posing infection or inflammatory risk to patients.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Clinical use of contaminated or unvalidated semaglutide could lead to adverse reactions requiring medical care. There is potential disruption to patient treatment schedules.

Practical Guidance

How to identify if yours is affected

  1. Check lot number CP-030-20250711
  2. Check expiry date July 24, 2027
  3. Confirm packaging and labeling from your supplier
  4. Cease use if matching identifiers

Where to find product info

Packaging labels display NDC codes and lot numbers; recall notices and FDA enforcement pages provide identifiers.

What timeline to expect

No refunds are described; recall remains active while manufacturers address CGMP issues.

If the manufacturer is unresponsive

  • Contact FDA recall hotline or submit a report via FDA recall portal
  • Work with healthcare provider to determine next steps
  • Consult state health department if provider is unresponsive

How to prevent similar issues

  • Source from FDA-registered, CGMP-compliant manufacturers
  • Verify endotoxin validation and process validation in supplier documentation
  • Maintain traceability of lots and NDCs for all compounded products

Documentation advice

Retain recall notices, communications from manufacturer, packaging labels with NDCs and lot numbers, and any adverse event reports.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Model numbers: CP-030-20250711; NDCs: 84385-106-01, 84385-106-02, 84385-106-06, 84385-106-03, 84385-106-04. Distribution: Nationwide in the United States to healthcare providers. Sold since unknown date. Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. Recall date: 2026-02-13. Status: ACTIVE. Expiry: July 24, 2027.

Key Facts

  • Distribution: Nationwide in the United States

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Model Numbers
CP-030-20250711
Exp. July 24, 2027
Affected States
ALL
Report Date
March 11, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

SUN PHARMACEUTICAL INDUSTRIES
Labeling: Not
Read more